 Keith Millikan
Concepts (261)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hernia, Ventral | 9 | 2018 | 24 | 2.150 |
Why?
| | Surgical Mesh | 11 | 2014 | 30 | 1.950 |
Why?
| | Herniorrhaphy | 9 | 2018 | 35 | 1.830 |
Why?
| | Hernia, Inguinal | 7 | 2016 | 22 | 1.500 |
Why?
| | Postoperative Complications | 20 | 2018 | 1059 | 1.370 |
Why?
| | Obesity, Morbid | 2 | 2017 | 78 | 1.290 |
Why?
| | Laparoscopy | 13 | 2016 | 186 | 1.180 |
Why?
| | Adenocarcinoma | 6 | 2016 | 233 | 1.150 |
Why?
| | Esophageal Neoplasms | 7 | 2002 | 60 | 1.070 |
Why?
| | Stomach Neoplasms | 3 | 2016 | 40 | 0.880 |
Why?
| | General Surgery | 4 | 2015 | 60 | 0.760 |
Why?
| | Cholecystectomy, Laparoscopic | 7 | 2015 | 38 | 0.690 |
Why?
| | Gastroplasty | 1 | 2016 | 28 | 0.670 |
Why?
| | Clinical Clerkship | 3 | 2013 | 27 | 0.650 |
Why?
| | Gastric Bypass | 1 | 2016 | 55 | 0.630 |
Why?
| | Middle Aged | 42 | 2018 | 11053 | 0.610 |
Why?
| | Carcinoma | 3 | 2016 | 83 | 0.600 |
Why?
| | Aged | 31 | 2018 | 9833 | 0.590 |
Why?
| | Male | 45 | 2020 | 17153 | 0.560 |
Why?
| | Treatment Outcome | 22 | 2018 | 3788 | 0.550 |
Why?
| | Educational Measurement | 3 | 2015 | 65 | 0.550 |
Why?
| | Digestive System Surgical Procedures | 2 | 2003 | 27 | 0.550 |
Why?
| | Recurrence | 10 | 2017 | 383 | 0.540 |
Why?
| | Humans | 60 | 2020 | 29841 | 0.530 |
Why?
| | Quality Improvement | 4 | 2014 | 169 | 0.510 |
Why?
| | Retrospective Studies | 25 | 2018 | 3303 | 0.500 |
Why?
| | Hepatectomy | 6 | 2015 | 61 | 0.500 |
Why?
| | Colonic Neoplasms | 3 | 2016 | 83 | 0.500 |
Why?
| | Adult | 30 | 2018 | 9591 | 0.490 |
Why?
| | Esophagectomy | 5 | 2002 | 24 | 0.480 |
Why?
| | Liver Neoplasms | 5 | 2000 | 124 | 0.470 |
Why?
| | Female | 42 | 2018 | 17657 | 0.470 |
Why?
| | Colectomy | 3 | 2016 | 33 | 0.470 |
Why?
| | Polytetrafluoroethylene | 2 | 2003 | 8 | 0.460 |
Why?
| | Curriculum | 2 | 2003 | 153 | 0.460 |
Why?
| | Pancreatic Neoplasms | 5 | 2013 | 172 | 0.400 |
Why?
| | Students, Medical | 2 | 2013 | 44 | 0.370 |
Why?
| | Aged, 80 and over | 13 | 2017 | 5016 | 0.350 |
Why?
| | Ambulatory Surgical Procedures | 3 | 2007 | 79 | 0.340 |
Why?
| | Risk Factors | 9 | 2018 | 2549 | 0.330 |
Why?
| | Survival Rate | 9 | 2015 | 464 | 0.320 |
Why?
| | Prospective Studies | 9 | 2014 | 1809 | 0.320 |
Why?
| | Smoking | 2 | 2016 | 195 | 0.310 |
Why?
| | Hernia, Hiatal | 2 | 2014 | 14 | 0.290 |
Why?
| | Polypropylenes | 1 | 2003 | 2 | 0.280 |
Why?
| | Gastrectomy | 3 | 2015 | 25 | 0.270 |
Why?
| | Ultrasonography | 4 | 2020 | 198 | 0.260 |
Why?
| | Cholangiography | 4 | 2015 | 12 | 0.260 |
Why?
| | Pancreaticoduodenectomy | 3 | 2013 | 37 | 0.250 |
Why?
| | Prognosis | 6 | 2017 | 1025 | 0.250 |
Why?
| | Follow-Up Studies | 7 | 2017 | 2017 | 0.250 |
Why?
| | Laparotomy | 3 | 2020 | 25 | 0.240 |
Why?
| | Colorectal Neoplasms | 4 | 1997 | 114 | 0.240 |
Why?
| | Hernia, Femoral | 1 | 2001 | 1 | 0.240 |
Why?
| | Mesenteric Cyst | 1 | 2020 | 1 | 0.230 |
Why?
| | Transforming Growth Factor alpha | 1 | 2000 | 7 | 0.220 |
Why?
| | Lymphokines | 1 | 2000 | 13 | 0.220 |
Why?
| | Endothelial Growth Factors | 1 | 2000 | 8 | 0.220 |
Why?
| | Peritoneum | 2 | 2003 | 19 | 0.220 |
Why?
| | Early Diagnosis | 1 | 2020 | 76 | 0.220 |
Why?
| | Elective Surgical Procedures | 2 | 2017 | 53 | 0.220 |
Why?
| | Neovascularization, Pathologic | 1 | 2000 | 70 | 0.210 |
Why?
| | United States | 9 | 2016 | 2402 | 0.210 |
Why?
| | Suture Techniques | 3 | 2007 | 138 | 0.200 |
Why?
| | Pneumonia | 2 | 2016 | 75 | 0.200 |
Why?
| | Carcinoma, Squamous Cell | 2 | 1997 | 193 | 0.200 |
Why?
| | Intra-Abdominal Hypertension | 1 | 2018 | 2 | 0.200 |
Why?
| | Compartment Syndromes | 1 | 2018 | 10 | 0.200 |
Why?
| | Adolescent | 6 | 2007 | 2591 | 0.200 |
Why?
| | Cholelithiasis | 1 | 1998 | 10 | 0.200 |
Why?
| | Gallstones | 1 | 1998 | 11 | 0.200 |
Why?
| | Cholecystectomy | 3 | 2013 | 16 | 0.190 |
Why?
| | Surgical Wound Infection | 3 | 2016 | 102 | 0.190 |
Why?
| | Lipoma | 1 | 2017 | 7 | 0.190 |
Why?
| | Myoepithelioma | 1 | 2017 | 4 | 0.180 |
Why?
| | Internship and Residency | 3 | 2015 | 182 | 0.180 |
Why?
| | Trachea | 1 | 1997 | 23 | 0.180 |
Why?
| | Survival Analysis | 6 | 2015 | 390 | 0.180 |
Why?
| | Mesenteric Vascular Occlusion | 1 | 1996 | 4 | 0.180 |
Why?
| | Liver | 2 | 1997 | 213 | 0.170 |
Why?
| | Soft Tissue Neoplasms | 1 | 2017 | 39 | 0.170 |
Why?
| | Databases, Factual | 5 | 2016 | 357 | 0.170 |
Why?
| | Analysis of Variance | 3 | 2003 | 369 | 0.170 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2016 | 7 | 0.170 |
Why?
| | Enterostomy | 1 | 2016 | 6 | 0.170 |
Why?
| | Portal Vein | 1 | 1996 | 46 | 0.160 |
Why?
| | Prostheses and Implants | 1 | 1997 | 168 | 0.160 |
Why?
| | Radiation Tolerance | 1 | 1995 | 8 | 0.160 |
Why?
| | Thrombosis | 1 | 1996 | 68 | 0.160 |
Why?
| | Fundoplication | 2 | 2013 | 24 | 0.160 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2015 | 9 | 0.160 |
Why?
| | Organs at Risk | 1 | 2015 | 16 | 0.160 |
Why?
| | Tumor Burden | 1 | 2015 | 43 | 0.160 |
Why?
| | Radiation Oncology | 1 | 2015 | 18 | 0.160 |
Why?
| | Liver Regeneration | 1 | 1995 | 27 | 0.160 |
Why?
| | Certification | 1 | 2015 | 57 | 0.160 |
Why?
| | Gallbladder Neoplasms | 1 | 2015 | 7 | 0.160 |
Why?
| | Esophagus | 2 | 2012 | 59 | 0.160 |
Why?
| | Appendectomy | 1 | 2014 | 10 | 0.150 |
Why?
| | Hospital Costs | 1 | 1996 | 74 | 0.150 |
Why?
| | Appendicitis | 1 | 2014 | 11 | 0.150 |
Why?
| | Abdominal Neoplasms | 1 | 2014 | 13 | 0.150 |
Why?
| | Ovarian Neoplasms | 1 | 2016 | 79 | 0.150 |
Why?
| | Safety | 2 | 2007 | 57 | 0.150 |
Why?
| | Body Mass Index | 1 | 2017 | 435 | 0.150 |
Why?
| | Image-Guided Biopsy | 1 | 2014 | 30 | 0.150 |
Why?
| | Neoplasm Staging | 5 | 2015 | 503 | 0.150 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 74 | 0.150 |
Why?
| | Lymphoma | 1 | 2014 | 57 | 0.150 |
Why?
| | Logistic Models | 4 | 2016 | 478 | 0.150 |
Why?
| | Clinical Competence | 3 | 2013 | 268 | 0.150 |
Why?
| | Biliary Dyskinesia | 1 | 2013 | 4 | 0.140 |
Why?
| | Cholestasis | 1 | 1993 | 9 | 0.140 |
Why?
| | Multivariate Analysis | 3 | 2016 | 390 | 0.140 |
Why?
| | Specialties, Surgical | 1 | 2013 | 6 | 0.140 |
Why?
| | Intestine, Small | 1 | 2014 | 37 | 0.140 |
Why?
| | Gallbladder Diseases | 1 | 2013 | 6 | 0.140 |
Why?
| | Surgical Procedures, Operative | 1 | 2013 | 38 | 0.140 |
Why?
| | Duodenal Neoplasms | 1 | 2013 | 10 | 0.140 |
Why?
| | Pain, Postoperative | 3 | 2013 | 293 | 0.140 |
Why?
| | Education, Medical, Undergraduate | 1 | 2013 | 35 | 0.140 |
Why?
| | Abdominal Wall | 1 | 2013 | 4 | 0.140 |
Why?
| | Operative Time | 4 | 2014 | 94 | 0.130 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2013 | 40 | 0.130 |
Why?
| | Sarcoma | 1 | 2015 | 110 | 0.130 |
Why?
| | Length of Stay | 5 | 2014 | 360 | 0.130 |
Why?
| | Education, Medical, Graduate | 1 | 2013 | 82 | 0.130 |
Why?
| | Severity of Illness Index | 1 | 2017 | 1220 | 0.130 |
Why?
| | Patient Satisfaction | 2 | 2013 | 298 | 0.130 |
Why?
| | Prosthesis Implantation | 2 | 2013 | 43 | 0.120 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 382 | 0.120 |
Why?
| | Sepsis | 1 | 2014 | 153 | 0.120 |
Why?
| | Stents | 1 | 1993 | 157 | 0.120 |
Why?
| | Esophageal Achalasia | 1 | 2012 | 22 | 0.120 |
Why?
| | Kidney | 1 | 2013 | 205 | 0.120 |
Why?
| | Morbidity | 3 | 2014 | 71 | 0.110 |
Why?
| | Lymph Node Excision | 2 | 2015 | 39 | 0.110 |
Why?
| | Time Factors | 4 | 2014 | 1894 | 0.110 |
Why?
| | Program Evaluation | 2 | 2013 | 150 | 0.100 |
Why?
| | Reoperation | 5 | 2016 | 911 | 0.100 |
Why?
| | Hernia, Abdominal | 1 | 2007 | 2 | 0.090 |
Why?
| | Polyurethanes | 1 | 2007 | 10 | 0.090 |
Why?
| | Omentum | 1 | 2007 | 10 | 0.090 |
Why?
| | Diagnosis, Differential | 3 | 2020 | 466 | 0.090 |
Why?
| | Statistics, Nonparametric | 2 | 2000 | 162 | 0.090 |
Why?
| | Chicago | 2 | 2001 | 916 | 0.090 |
Why?
| | Child | 3 | 2001 | 1505 | 0.080 |
Why?
| | Sutures | 2 | 2003 | 42 | 0.080 |
Why?
| | Age Factors | 2 | 2016 | 912 | 0.080 |
Why?
| | Anastomosis, Surgical | 2 | 2016 | 56 | 0.080 |
Why?
| | Sensitivity and Specificity | 3 | 2007 | 592 | 0.070 |
Why?
| | Algorithms | 2 | 2015 | 414 | 0.070 |
Why?
| | Longitudinal Studies | 1 | 2007 | 1388 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 4 | 2015 | 869 | 0.070 |
Why?
| | Comorbidity | 2 | 2016 | 555 | 0.070 |
Why?
| | Minimally Invasive Surgical Procedures | 2 | 2014 | 288 | 0.060 |
Why?
| | Vascular Diseases | 1 | 2002 | 53 | 0.060 |
Why?
| | Disease-Free Survival | 2 | 2000 | 245 | 0.060 |
Why?
| | Confidence Intervals | 1 | 2002 | 105 | 0.060 |
Why?
| | Probability | 1 | 2002 | 107 | 0.060 |
Why?
| | Models, Educational | 1 | 2001 | 39 | 0.060 |
Why?
| | Workload | 1 | 2001 | 39 | 0.060 |
Why?
| | Bile | 1 | 2020 | 6 | 0.060 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2000 | 10 | 0.060 |
Why?
| | von Willebrand Factor | 1 | 2000 | 11 | 0.060 |
Why?
| | Intraoperative Care | 2 | 1998 | 58 | 0.060 |
Why?
| | Barrett Esophagus | 1 | 2000 | 19 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2000 | 75 | 0.050 |
Why?
| | Lymphatic Metastasis | 1 | 2000 | 109 | 0.050 |
Why?
| | Endosonography | 1 | 1999 | 15 | 0.050 |
Why?
| | Risk Assessment | 2 | 2017 | 794 | 0.050 |
Why?
| | Adenocarcinoma, Papillary | 1 | 1999 | 2 | 0.050 |
Why?
| | Infant | 1 | 2001 | 652 | 0.050 |
Why?
| | Child, Preschool | 1 | 2001 | 785 | 0.050 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 1998 | 9 | 0.050 |
Why?
| | Liver Function Tests | 1 | 1998 | 32 | 0.050 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2000 | 210 | 0.050 |
Why?
| | Patient Selection | 1 | 2000 | 249 | 0.050 |
Why?
| | Bronchial Neoplasms | 1 | 1997 | 14 | 0.050 |
Why?
| | Groin | 1 | 2017 | 6 | 0.050 |
Why?
| | Infant, Newborn | 1 | 2020 | 741 | 0.050 |
Why?
| | Incidental Findings | 1 | 2017 | 18 | 0.050 |
Why?
| | Thigh | 1 | 2017 | 36 | 0.050 |
Why?
| | Combined Modality Therapy | 2 | 1997 | 467 | 0.050 |
Why?
| | Neoplasm Invasiveness | 1 | 1997 | 104 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2017 | 86 | 0.050 |
Why?
| | Pilot Projects | 2 | 1997 | 425 | 0.040 |
Why?
| | Intestinal Polyps | 1 | 1996 | 1 | 0.040 |
Why?
| | Mesenteric Veins | 1 | 1996 | 1 | 0.040 |
Why?
| | Sigmoid Neoplasms | 1 | 1996 | 1 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2017 | 119 | 0.040 |
Why?
| | Angina Pectoris | 1 | 2016 | 19 | 0.040 |
Why?
| | Cryosurgery | 1 | 1997 | 30 | 0.040 |
Why?
| | Peripheral Vascular Diseases | 1 | 2016 | 14 | 0.040 |
Why?
| | Rectal Neoplasms | 1 | 1996 | 27 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 1998 | 617 | 0.040 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 40 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2017 | 497 | 0.040 |
Why?
| | Cost Savings | 1 | 1996 | 39 | 0.040 |
Why?
| | Liver Neoplasms, Experimental | 1 | 1995 | 1 | 0.040 |
Why?
| | Bilirubin | 1 | 1995 | 14 | 0.040 |
Why?
| | Cardia | 1 | 1995 | 3 | 0.040 |
Why?
| | Aspartate Aminotransferases | 1 | 1995 | 19 | 0.040 |
Why?
| | Alanine Transaminase | 1 | 1995 | 24 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 1996 | 144 | 0.040 |
Why?
| | Diabetes Mellitus | 1 | 2016 | 131 | 0.040 |
Why?
| | Intestines | 1 | 2016 | 103 | 0.040 |
Why?
| | Random Allocation | 1 | 1995 | 162 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 1995 | 146 | 0.040 |
Why?
| | Observer Variation | 1 | 2015 | 140 | 0.040 |
Why?
| | Ultrasonography, Interventional | 1 | 2015 | 73 | 0.040 |
Why?
| | Consensus | 1 | 2015 | 90 | 0.040 |
Why?
| | Jejunum | 1 | 1994 | 14 | 0.040 |
Why?
| | Surgical Stapling | 1 | 1994 | 9 | 0.040 |
Why?
| | Hospitals, University | 1 | 1994 | 45 | 0.040 |
Why?
| | Sex Factors | 1 | 2016 | 524 | 0.040 |
Why?
| | Hypertension | 1 | 2016 | 266 | 0.040 |
Why?
| | Digestive System Neoplasms | 1 | 1993 | 6 | 0.040 |
Why?
| | Radiography | 1 | 1996 | 714 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 1 | 1995 | 481 | 0.040 |
Why?
| | Blood Transfusion | 1 | 2014 | 68 | 0.040 |
Why?
| | Attitude of Health Personnel | 1 | 2015 | 177 | 0.040 |
Why?
| | Illinois | 1 | 2014 | 265 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2015 | 178 | 0.030 |
Why?
| | Ileus | 1 | 2013 | 4 | 0.030 |
Why?
| | Seroma | 1 | 2013 | 4 | 0.030 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2013 | 19 | 0.030 |
Why?
| | Wound Healing | 1 | 2014 | 171 | 0.030 |
Why?
| | Lumbar Vertebrae | 1 | 1999 | 433 | 0.030 |
Why?
| | Rats | 1 | 1995 | 941 | 0.030 |
Why?
| | Device Removal | 1 | 2013 | 97 | 0.030 |
Why?
| | Spinal Fusion | 1 | 1999 | 425 | 0.030 |
Why?
| | Intraoperative Period | 3 | 1997 | 40 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 1995 | 813 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2013 | 684 | 0.030 |
Why?
| | Cohort Studies | 1 | 2015 | 1911 | 0.030 |
Why?
| | Surgical Instruments | 1 | 2007 | 24 | 0.020 |
Why?
| | Quality of Life | 1 | 2013 | 604 | 0.020 |
Why?
| | Ischemia | 1 | 2007 | 32 | 0.020 |
Why?
| | Blood Loss, Surgical | 2 | 1999 | 71 | 0.020 |
Why?
| | Animals | 1 | 1995 | 5125 | 0.020 |
Why?
| | Prosthesis Design | 1 | 2007 | 499 | 0.020 |
Why?
| | Pancreatitis | 1 | 2002 | 27 | 0.020 |
Why?
| | Medical Records | 1 | 2002 | 40 | 0.020 |
Why?
| | Chronic Disease | 1 | 2002 | 530 | 0.010 |
Why?
| | Cystadenocarcinoma | 1 | 1999 | 1 | 0.010 |
Why?
| | Cystadenoma | 1 | 1999 | 1 | 0.010 |
Why?
| | Retroperitoneal Space | 1 | 1999 | 14 | 0.010 |
Why?
| | Orthopedic Fixation Devices | 1 | 1999 | 24 | 0.010 |
Why?
| | Fluorouracil | 1 | 1997 | 89 | 0.010 |
Why?
| | Radiotherapy Dosage | 1 | 1997 | 146 | 0.010 |
Why?
| | Cisplatin | 1 | 1997 | 107 | 0.010 |
Why?
| | Feasibility Studies | 1 | 1997 | 273 | 0.010 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 1994 | 7 | 0.010 |
Why?
| | Esophagogastric Junction | 1 | 1994 | 13 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1997 | 408 | 0.010 |
Why?
| | Puerto Rico | 1 | 1993 | 15 | 0.010 |
Why?
| | Bile Ducts | 1 | 1993 | 12 | 0.010 |
Why?
| | Data Collection | 1 | 1993 | 118 | 0.010 |
Why?
| | Intraoperative Complications | 1 | 1993 | 75 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 1997 | 1220 | 0.010 |
Why?
|
|
Millikan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|